AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions of claims in the application.

1-30 (cancelled).

1. (new) A compound represented by the following formula:

or a pharmaceutically acceptable salt thereof wherein:

X¹ - X³ are independently C or N; X⁴ is CH or N, wherein not more than two of X¹ - X⁴ is N; X⁶ - X⁸ are independently C or N;

X⁹ is CH or N, wherein not more than two of X⁶ - X⁹ is N;

 X^5 is N, R^5 is a lone pair, and X^{10} is CH, when the bond between X^5 and X^{10} is a double bond; or X^5 is CH, R^5 is H, and X^{10} is CH₂, when the bond between X^5 and X^{10} is a single bond; or X^5 is C, R^5 is defined below, and X^{10} is CH, when the bond between X^5 and X^{10} is a double bond;

 R^1 - R^3 and R^6 - R^8 represent a lone pair or O when each respective X^1 - X^3 and X^6 - X^8 is N; or when X^1 - X^3 or X^6 - X^8 is C, each respective R^1 - R^3 and R^6 - R^8 is independently selected from the group consisting of:

- a) H, substituted or unsubstituted C(1-8) alkyl, halogen, azido, cyano, nitro, or NR²¹R²², wherein R²¹ represents H or C(1-8) alkyl, and R²² represents H, substituted or unsubstituted C(1-8) alkylcarbonyl, substituted or unsubstituted arylcarbonyl, heterocycle, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted C(1-8) alkylaminocarbonyl, substituted or unsubstituted arylaminocarbonyl;
- b) OR²³, wherein R²³ is H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl;
- c) SR²³, wherein R²³ is defined as in b);
- d) O(CH₂)_j-R²⁴, O(CH₂)_j-O-R²⁴, or O(CH₂)_j-S-R²⁴, wherein j is an integer from 1 to 8, and R²⁴ is selected from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
- e) $S(CH_2)_jR^{24}$, $S(CH_2)_j$ -O-R²⁴, or $S(CH_2)_j$ -S-R²⁴, wherein j and R²⁴ are defined as in d);
- f) C≡C-R²⁵, C≡C-OR²⁵, or C≡C-CO₂R²⁵, wherein R²⁵ is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- g) CH=CH-R²⁵, CH=CH-OR²⁵, or CH=CH-CO₂R²⁵, having a stereochemistry of E or Z, and R²⁵ is defined as in f);
- h) $C = C NR^{25}R^{26}$ or $C = CCONR^{25}R^{26}$, wherein R^{25} is defined as in f), and R^{26} is defined as R^{25} , and R^{25} and R^{26} are selected independently;
- i) CH=CH-NR²⁵R²⁶ or CH=CHCONR²⁵R²⁶, having a stereochemistry of E or Z, wherein R²⁵ and R²⁶ are independently defined as in h);
- j) $(CH_2)_kR^{25}$, $(CH_2)_k$ -COOR²⁵, or $(CH_2)_k$ -OR²⁵, wherein k is an integer from 2 to 6 and R²⁵ is defined as in f);
- k) $(CH_2)_kNR^{25}R^{26}$, $(CH_2)_kCONR^{25}R^{26}$, wherein R^{25} and R^{26} are selected independently, and R^{25} and R^{26} are defined as R^{25} in f); and
- I) CH₂XR²⁷, wherein X is O or S and R²⁷ is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

R⁴ is selected from the group consisting of:

m) H, substituted or unsubstituted C(1-8) alkyl; and

n)

wherein X=O, S, or NH, n=1 to 4; and wherein R⁵¹ is H; R⁵² and R⁵³ are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8)alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R⁵¹ and R⁵² are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system;

R⁵ is selected from the group consisting of:

- o) a lone pair when X^5 is N; or when X^5 is C, R^5 is selected from the group consisting of:
 - p) H, substituted and unsubstituted C(1-8) alkyl; and

q)

wherein X=O, S, or NH, n=1 to 4; and wherein R⁵¹ is H; R⁵² and R⁵³ are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R⁵¹ and R⁵² are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system; or

wherein when R^1 - R^3 and R^5 - R^8 are H, and R^4 is H or CH_3 , then at least one of $X^1 - X^9$ represents a ring member other than carbon.

- 2. (new) A compound, according to claim 1, in which X¹ X³ are independently C.
- 3. (new) A compound, according to claim 1, in which X⁴ is CH.
- 4. (new) A compound, according to claim 1, in which X⁶ X⁸ are independently C.
- 5. (new) A compound, according to claim 1, in which X⁹ is CH or N.
- 6. (new) A compound, according to claim 1, in which X^5 is C, X^{10} is CH and the bond between X^5 and X^{10} is a double bond.

- 7. (new) A compound, according to claim 1, in which X^5 is N, R^5 is a lone pair, X^{10} is CH and the bond between X^5 and X^{10} is a double bond.
- 8. (new) A compound, according to claim 1, in which X^5 is CH, R^5 is H, X^{10} is CH₂ and the bond between X^5 and X^{10} is a single bond.
- 9. (new) A compound having the following formula:

wherein X⁵ is C or N, and X¹-X³, X⁴, X⁶-X⁸, R¹-R³, R⁴, R⁵ and R⁶-R⁸ are as defined in claim 1.

10. (new) A compound having the following formula:

wherein X^1 - X^3 , X^4 , X^6 - X^8 , R^1 - R^3 , R^4 , R^5 and R^6 - R^8 are as defined in claim 1.

11. (new) A compound having the following formula:

wherein X^1 - X^3 , X^4 , X^6 - X^8 , R^1 - R^3 , R^4 , R^5 and R^6 - R^8 are as defined in claim 1.

12. (new) A compound having the following formula:

wherein X¹-X³, X⁴, X⁶-X⁸, R¹-R³, R⁴, R⁵ and R⁶-R⁸ are as defined in claim 1.

13. (new) A compound, according to claim 1, in which when $X^1 - X^3$ or $X^6 - X^8$ is C, each respective $R^1 - R^3$ and $R^6 - R^8$ is independently selected from the group consisting of:

- a) H, halogen;
- b) OR²³, wherein R²³ is H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl; and
- d) O(CH₂)_j-R²⁴, O(CH₂)_j-O-R²⁴, or O(CH₂)_j-S-R²⁴, wherein j is an integer from 1 to 8, and R²⁴ is selected from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.

14. (new) A compound, according to claim 1, in which R⁴ is selected from the group consisting of:

m) H, substituted or unsubstituted C(1-8) alkyl; and

n)

wherein X=O, S, or NH, n=2; and wherein R⁵¹ is H; R⁵² and R⁵³ are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8)alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R⁵¹ and R⁵² are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

15. (new) A compound, according to claim 14, in which R⁴ is selected from the group consisting of:

m) H, substituted or unsubstituted C(1-8) alkyl; and

n)

wherein X=S, n=2; and wherein R^{51} is H; R^{52} and R^{53} are both H, or R^{51} and R^{52} are combined to form a heteroaryl ring system.

16. (new) A compound, according to claim 15, in which R⁴ is selected from the group consisting of: H, methyl, CH₂CH₂CH₂OH, CH₂CH₂CH₂NH₂, CH₂CH₂CH₂N₃,

- 17. (new) A compound, according to claim 1, in which X⁵ is N and R⁵ is a lone pair.
- 18. (new) A compound, according to claim 1, in which X⁵ is C or CH, and R⁵ is selected from the group consisting of:
 - p) H, substituted and unsubstituted C(1-8) alkyl; and

q)

wherein X=S, n=2; and wherein R^{51} is H; R^{52} and R^{53} are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R^{51} and R^{52} are combined to form a heteroalkyl, substituted heteroaryl, or substituted heteroaryl ring system.

19. (new) A compound, according to claim 18, in which X⁵ is C or CH, and R⁵ is selected from the group consisting of H, methyl, CH₂CH₂CH₂OH, CH₂CH₂CH₂CH₂CH₂CH₂NH)NH₂,

$$\label{eq:ch2CH2CH2CH2N} CH_2CH_2CH_2N(CH_3)_2,\ CH_2CH_2CH_2N_3,\ CH_2CH_2CH_2NH_2,\ and$$

20. (new) A compound, according to the following formula

$$R^3$$
 X^{10}
 R^5
 R^5

selected from the group consisting of:

Cpd.	Bond between X ⁵ /X ¹⁰	R ³	R ⁵⁰	R ⁷	X ⁵ /R ⁵	X ₉	X ¹⁰
121	Double	Н	-OH	Н	CH	CH	CH
124	Double	BnO	-OH	Н	CH	CH	CH
125	Double	Н	-OH	Н	CMe	CH	CH
126	Double	Н	-OH	BnO	CH	CH	CH
127	Double	Н	-OH	Н	CH	CH	CMe
128	Double	Н	-OH	Н	N	CH	CH
129	Double	BnO	-OH	Н	CMe	CH	CH
130	Double	Н	-OH	Н	СН	N	СН
131	Double	BnO	-OH	Н	CH	CH	CMe
132	Double	Н	-OH	F	CH	CH	CH
133	Double	Н	-N(CH ₃) ₂	H	CH	CH	CH
136	Double	BnO	-N(CH ₃) ₂	Н	CH	CH	СН
137	Double	Н	-N(CH ₃) ₂	Н	СМе	CH	СН
138	Double	Н	-N(CH ₃) ₂	BnO	CH	CH	CH
139	Double	Н	-N(CH ₃) ₂	Н	CH	CH.	CMe
140	Double	Н	-N(CH ₃) ₂	Н	N	CH	CH
141	Double	BnO	-N(CH ₃) ₂	Н	CMe	СН	СН
142	Double	Н	-N(CH ₃) ₂	Н	CH	N	CH
143	Double	Н	-SC(=NH)NH ₂	Н	CH	CH	CH

Cpd.	Bond between X ⁵ /X ¹⁰	R³	R ⁵⁰	R ⁷	X ⁵ /R ⁵	Xª	X ¹⁰	
146	Double	Н	-SC(=NH)NH₂	Н	CMe	СН	CH	」 ;
147	Double	HH	-SC(=NH)NH₂	BnO	CH	CH	CH	<u></u>];
148	Double	BnO	-SC(=NH)NH ₂	H	CH	CH	CH];
149	Double	BnO	-SC(=NH)NH ₂	H.	CH	СМе	CH];
150	Double	BnO	-SC(=NH)NH ₂	Н	CH	СН	CMe];
151	Double	Н	-SC(=NH)NH ₂	Н	CH	CH	CMe];
152	Double	Н	-SC(=NH)NH ₂	H	CH	N	CH];
153	Double	MeO	-SC(=NH)NH ₂	Н	CH	CH	CH];
154	Double	F	-SC(=NH)NH ₂	Н	CH	CH	СН];
155	Double	H	-SC(=NH)NH ₂	F	CH	CH	CH];
156	Double	Η	S N	Н	СН	СН	CH];
159	Single	Н	-SC(=NH)NH₂	Н	CH₂	СН	CH₂];
160	Double	OCH₂S Ph	-SC(=NH)NH₂	Н	СН	СН	CH];
161	Double .	Н	-N ₃	Н	СН	. CH	СН	; and
162	Double	Н	-NH ₂	Н	СН	СН	СН] .

21. (new) A compound according to the following formula:

$$R^3$$
 R^4
 R^{50}

selected from the group consisting of:

Example	R³	R ⁵⁰	R ⁷	R⁴
163	Н	ОН	Н	Н
164	Н	ОН	Н	Ме
165	BnO	ОН	Н	Н .
166	Н	SC(=NH)NH ₂	Н	Н

167	Н	SC(=NH)NH ₂	Н	Me];
168	BnO	SC(=NH)NH ₂	Н	Me	 ;
169	Н	N(CH ₃) ₂	H	Me	 ;
170	Н	Z S Z H	Н	Ме];
171	H	N ₃	Н	Me	; and
172	Н	NH ₂	Н	Me	1.

- 22.(new) A composition comprising a compound, according to claim 1, in combination with carrier.
- 23. (new) The composition, according to claim 22, further including a chemotherapeutic agent.
- 24. (new) The composition, according to claim 22, further including a cytokine.
- 25. (new) The composition, according to claim 22, further including anti-sense oligonucleotides.
- 26. (new) A method of treating an inflammatory disorder, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat the disorder.
- 27. (new) A method of treating cancer, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat the cancer.
- 28. (new) A method of treating a cell proliferative disorder, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat the disorder.

- 29. (new) A method of treating cancer, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, in combination with another chemotherapeutic agent.
- 30. (new) Use of a compound or a composition, according to claim 1 or 22, so as to induce apoptosis in Jurkat cells.
- 31. (new) Use of a compound or a composition, according to claim 1 or 22, so as to induce apoptosis in cancer cell lines.
- 32. (new) The use, according to claim 31, in which the cancer cell lines are prostate cancer and breast cancer cell lines
- 33. (new) A method of treatment or prevention of a condition resulting from loss of growth and cellular differentiation control, the method comprising: administration to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat or prevent the condition.